CytomX Therapeutics is a biopharmaceutical company that researches and develops therapies to combat cancer by using the disease's own mechanisms against itself.

CytomX Therapeutics

CytomX Therapeutics, Inc. is committed to changing the treatment of cancer with our novel Probody® therapeutic platform. We have a broad pipeline comprised of five clinical-stage programs, with even more in development. 

Our commitment to transforming lives with safer, more effective therapies is driven by our curiosity and passion for innovation, and our belief that by acting with integrity in an honest, respectful, ethical manner, we have the power to change lives. Our workplace embodies collaboration, open communication, celebrating our successes and holding each other to the highest possible standards. 

CytomX embraces diversity and seeks to enhance and maintain our culture of equity and inclusion which encourages individuals to be themselves, feel involved, respected and connected.

We at CytomX believe that we benefit from each other’s ideas and experiences. We accept our differences and learn from one another, improve together, and embrace change to achieve our corporate and individual objectives. This belief applies to how we work together at CytomX, how we work with others outside CytomX, how we represent CytomX in our communities, and how we endeavor to bring our scientific innovations to a diverse patient population.

CytomX acknowledges the importance of diversity, equity and inclusion initiatives and that they require an evolving and ongoing commitment. CytomX is an equal opportunity employer and does not discriminate against any individual or potential candidate because of race, color, religion, sex, national origin, sexual preference or any other legally protected category.

CytomX is located in South San Francisco, California, the birthplace of biotechnology. Learn more about us and how we are advancing science to treat cancer differently at www.cytomX.com.

Canaan Partners

Third Rock Ventures

Casdin Capital

Wellington Management

Perceptive Advisors

Redmile Group

Cormorant Asset Management

Deerfield

Tekla Capital Management

Venrock

Today we announced second quarter 2024 financial results, including progress related to our clinical-stage PROBODY® therapeutic programs. To learn more, read our press release and join our conference call and webcast at 5pm ET/2pm PT. https://lnkd.in/evS2MHHC

Happy National Intern Day! At CytomX, CREATIVITY is more than just a value—it's at the heart of everything we do. As we celebrate National Intern Day, we applaud our interns for embodying this core value, infusing their work in science with fresh perspectives and innovative thinking. They are the future of scientific discovery, paving the way for the next generation of leaders. Here's to the next generation of leaders shaping the future at CytomX!

Celebrating International Women's History Month at CytomX! As a culture that embraces diversity, we proudly honor the invaluable contributions of women in STEM. With over half of our organization being women, we recognize their significant impact and dedication. At CytomX, one of our values is COMMITMENT, and we are dedicated to our patients, teammates, and fostering a diverse and inclusive environment where everyone thrives. Here's to the inspiring women shaping the future of science and making significant impacts every day!

Happy Lunar New Year! This year marks the beginning of the Wood Dragon, symbolizing creativity and adaptability. At CytomX, we embrace CREATIVITY as one of our core values, as we believe that curiosity and innovation have the power to change lives! To celebrate, we hosted a special Lunar New Year Happy Hour, where we toasted the year ahead and honored the spirit of innovation that defines our work. Wishing everyone a prosperous and joyful year ahead! 🐲 🎊

At CytomX, our mission is to transform the lives of cancer patients with safer, more effective therapies through the development of novel conditionally activated biologics. Watch our CEO Sean McCarthy's recent conversation with
Precision AQ to learn more!

Today at 2pm ET, our chief executive officer and chairman Sean McCarthy will participate in a fireside chat at the H.C. Wainwright & Co., LLC 2nd Annual Immune Cell Engager Virtual Conference. Tune into the webcast to listen live or hear the replay: https://lnkd.in/e8FurEhJ

Viewport Meta

IPhone / Mobile Compatible

Euro

HSTS

Google Font API

Google Analytics

Google Maps

WordPress

Amazon

Google Universal Analytics

Senior Vice President, CMO

Alison Hannah

Chief Development Officer

Amy Peterson

Vice President and Associate General Counsel

Daniel Woubishet

Chief Operating Officer & Chief Business Officer

Halley Gilbert

Chief Business Officer and Head of Strategy

Jeff Landau

Chief Executive Officer

Sean McCarthy

Vice President Alliance Management

Alison Joly

VP, Investor Relations & Corporate Communications

Chau Cheng

Senior Vice President, Finance and Accounting

Chris Ogden

Senior Vice President, Talent and Systems Development

Danielle Olander-Moghadassian

Hoyoung Huh

Charles Homcy

Neil Exter

John Maraganore

Fred Gluck

Timothy Shannon

HALLEY GILBERT

Carol Talkington Verser

Sr. Director & Head, Intellectual Property

James W. West

Research Fellow

Michael Kavanaugh

Member, Scientific Advisory Board

Yu-Waye Chu

Chief Medical Officer

Director of Research

Health Care Companies With More Than $50M in Revenue (Top 10K)

Pharmaceutical Public Companies

Therapeutics Female Founded Companies

Biotechnology Companies With More Than 10 Employees (Top 10K)

CytomX Therapeutics is a biotechnology company that focuses on developing proteolytically-activated antibodies. Their mission, alone and with the help of partners, is to provide patients with more effective and less toxic therapies for severe illnesses such as cancer and inflammatory diseases.

Post-IPO Equity - CytomX Therapeutics

Series D - CytomX Therapeutics

Pfizer Venture Investments

Series C - CytomX Therapeutics

Series B - CytomX Therapeutics

Convertible Note - CytomX Therapeutics

South San Francisco

California

United States

North America

HC Wainwright & Co. Reiterates Neutral on Cyt...

CytomX Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

CytomX Therapeutics to Present at Upcoming September Investor Conferences

CytomX Therapeutics files $250M mixed securities shelf

CytomX Therapeutics reports Q2 EPS (8c), consensus (14c)

CytomX Therapeutics Promotes Chris Ogden to CFO

CytomX Therapeutics Promotes Chris Ogden to Chief Financial Officer

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q1 2024 Earnings Call Transcript

Probody therapeutics are designed to activate only in the presence of cancer, minimizing activity in healthy tissue. They utilize tumor-specific proteases to remove a masking peptide, allowing the therapeutic to bind to its target.

CX-904 is a T-cell-engaging bispecific Probody targeting EGFR on cancer cells and CD3 on T cells, currently in Phase 1 clinical trials for advanced solid tumors.

CX-2051 is a conditionally activated antibody-drug conjugate targeting EpCAM, designed for epithelial cancers. It aims to provide systemic treatment while limiting exposure to normal tissues.

CX-801 is a conditionally activated interferon alpha-2b Probody, designed to enhance tolerability and antitumor effects by activating primarily in the tumor microenvironment.

United Kingdom

Europe

Australia

Oceania

India

Asia

Georgia

HTML5

Google Compute Engine

Office 365

Facebook Comments

Vimeo

F5 NGINX

Microsoft Outlook

Adobe Flash

GoDaddy

Modernizr

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors. It also develops CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, as well as CX-904, a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

news impact assignment basic	general
public peers	general	Aug 31, 2024 7:30 PM	27fbee84
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general	Nov 25, 2024 9:06 AM	971d0aaa
crunchbase profile	general	Nov 25, 2024 10:34 AM	2417396d
li profile	general	Aug 31, 2024 7:30 PM	86cf91c2
translate crunchbase fundingrounds	general	Nov 25, 2024 4:24 PM	b2c7fd72
peers	general	Aug 31, 2024 7:30 PM	60f1cbac
news basic	general	Aug 31, 2024 7:30 PM	59e15b72
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:CYTOMX

CytomX Therapeutics

Last Close

0.87

22/11 21:00

Market Cap

102.07M

Beta: -

Volume Today

1.23K

Avg: -